Although ATM mutations in CRC have shown promising results with PARPi, there is no universally accepted biomarker to reliably predict response to PARP inhibitors in colon cancer, which can lead to suboptimal patient selection and treatment outcomes [94]. The gene discussed is PARP1; the disease is colorectal carcinoma.